Form 4: Tenet Healthcare CEO Sells $15M in Stock Under 10b5-1 Plan

Tenet Healthcare CEO Saumya Sutaria sold 78,762 shares of common stock for approximately $15 million in two pre-arranged transactions on September 10, 2025.

Summary

• Saumya Sutaria, CEO and Director of Tenet Healthcare Corp (THC), sold a total of 78,762 shares of common stock.
• The sales occurred in two separate transactions on September 10, 2025, and were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• The first transaction involved 59,456 shares sold at a weighted average price of $190.48 per share, with individual sales ranging from $190.14 to $191.05.
• The second transaction involved 19,306 shares sold at a weighted average price of $191.70 per share, with individual sales ranging from $191.18 to $192.06.
• Following these transactions, Sutaria beneficially owns 368,683 shares of Tenet Healthcare common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, the disclosure that the transactions were made pursuant to a Rule 10b5-1 plan mitigates concerns that the sale is based on new, negative material non-public information. It suggests a pre-planned financial management decision.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating a pre-arranged, non-discretionary sale rather than a reaction to new, material non-public information, which mitigates potential negative market interpretations.

Negatives

• Insider selling by a CEO and Director can be perceived negatively by the market, potentially signaling a belief that the stock is fully valued or a lack of confidence, despite the 10b5-1 plan.
• The sale represents a significant reduction in the CEO's direct beneficial ownership, decreasing by 78,762 shares from 387,989 to 368,683 shares.

Risks

• Market perception of insider selling, even when pre-planned, could lead to negative investor sentiment or downward pressure on the stock price.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• Not applicable as this filing details an individual insider stock transaction rather than company performance metrics or project results.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal regarding management's view on the company's valuation, potentially leading to a slight negative sentiment, although the 10b5-1 plan mitigates this.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person.

Key Dates

Recommendation

While insider selling by a CEO can sometimes be a bearish signal, the disclosure that these transactions were conducted under a Rule 10b5-1 plan suggests a pre-scheduled, non-discretionary sale for personal financial management rather than a reaction to new, negative company-specific information. This mitigates the negative implications, leading to a 'hold' recommendation as the filing itself does not provide new fundamental information to alter the investment thesis, but rather reports a routine insider transaction.

Keywords

Tenet Healthcare, THC, Insider Sale, Form 4, Saumya Sutaria, CEO, Stock Sale, 10b5-1 Plan, Healthcare Stock